Whether CD44 is an applicable marker for glioma stem cells.

ABSTRACT: Glioblastoma multiforme (GBM) is one of the most malignant and aggressive brain tumors with great amount of hyaluronan (HA) secretion and CD44 overexpression (HA receptor). CD44 has been suggested as a cancer stem cells (CSCs) marker. However, several clinical studies have indicated that CD44^low glioma cell exhibit CSCs traits. Additionally, our previous study indicated that more CD44 expression was associated with a better prognosis in GBM patients. To determine whether CD44 is an appropriate marker of glioma stem cells (GSCs), we manipulated CD44 expression using intrinsic (CD44 knockdown, CD44^kd) and extrinsic (HA supplement, HA⁺) methods. Our results show that CD44^kd suppressed cell proliferation by retarding cell cycle progression from G0/G1

SUBMITTER: Wang HH 

PROVIDER: S-EPMC5714766 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature